First Brazilian position on resistant hypertension

Arquivos Brasileiros de Cardiologia

Volumn 99, Issue 1, 2012, Pages 576-585

  de Souza, Weimar Sebba Barroso ^a  

^a NONE

Author keywords

Antihypertensive agents administration dosage; Antihypertensive agents therapeutic use dosage; Blood pressure; Hypertension diet therapy; Hypertension physiopathology; Risk factors

Indexed keywords

CHLORTALIDONE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ALCOHOL CONSUMPTION; AORTA ATHEROSCLEROSIS; AORTOGRAPHY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BRAIN DISEASE; BRAZIL; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID SINUS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIET SUPPLEMENTATION; DISEASE CONTROL; DISEASE SEVERITY; ECHOGRAPHY; GLOMERULUS FILTRATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY ARTERIOGRAPHY; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; LACUNAR STROKE; NEPHROSCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ATTITUDE; PHENOTYPE; PHYSICAL ACTIVITY; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIMARY HYPERALDOSTERONISM; PROGNOSIS; RESISTANT HYPERTENSION; SALT INTAKE; SLEEP APNEA SYNDROME; SODIUM INTAKE; SYMPATHETIC NERVE; WEIGHT REDUCTION; WHITE COAT HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BRAZIL; DRUG RESISTANCE; HUMANS; HYPERTENSION;

EID: 84866177720     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2012000700002     Document Type: Article

References (76)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-19.
2. Sander GE, Giles TD. Resistant hypertension: concepts and approach to management. Curr Hypertens Rep. 2011;13(5):347-55.
3. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22(1):11-9
4. Sociedade Brasileira de Cardiologia/Sociedade Brasileira de Hipertensão /Sociedade Brasileira de Nefrologia. VI Diretrizes brasileiras de hipertensão arterial. Arq Bras Cardiol. 2010;95(1 supl.1):1-51.
5. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-50.
6. McAlister FA, Wilkins K, Joffres M, Leenen FH, Fodor G, Gee M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ. 2011;183(9):1007-13.
7. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42.
8. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence and prognosis. Circulation. 2012;125(13):1594-6.
9. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-80.
10. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046-58.
11. Pimenta E, Calhoun DA. Treatment of resistant hypertension. J Hypertens. 2010;28(11):2194-5.
12. Pimenta E. Update on diagnosis and treatment of resistant hypertension. Iran J Kidney Dis. 2011;5(4):215-27.
13. de La Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898-902.
14. Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? J Hypertens. 2008;26(5):878-84.
15. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22(11):2217-26.
16. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008;51(2):339-44.
17. Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab. 2011;96(9):2813-20.
18. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475-81.
19. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168(21):2340-6.
20. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56(5):824-30.
21. White WB. Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment. J Clin Hypertens (Greenwich). 2007;9(1 Suppl1):25-30.
22. Cittadino M, Goncalves de Sousa M, Ugar-Toledo JC, Rocha JC, Tanus Santos JE, Moreno H Jr. Biochemical endothelial markers and cardiovascular remodeling in refractory arterial hypertension. Clin Exp Hypertens. 2003;25(1):25-33.
23. Salles GF, Cardoso CR, Pereira VS, Fiszman R, Muxfeldt ES. Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study. J Hypertens. 2011;29(10):2014-23.
24. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162(4):413-20.
25. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations of blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697-716.
26. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012;379(9819):905-14.
27. de la Sierra A, Larrousse M, Oliveras A, Armario P, Hernández-Del Rey R, Poch E, et al. Abnormalities of vascular function in resistant hypertension. Blood Press. 2012;21(2):104-9.
28. Muxfeldt ES, Fiszman R, Castelpoggi CH, SallesGF. Ambulatory arterial stiffness index or pulse pressure: which correlates better with arterial stiffness in resistant hypertension? Hypertens Res. 2008;31(4):607-13.
29. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011;25(9):532-8.
30. Figueiredo VN, Yugar-Toledo JC, Martins LC, Martins LB, de Faria AP, de Haro Moraes C, et al. Vascular stiffness and endothelial dysfunction: correlations at different levels of blood pressure. Blood Press. 2012;21(1):31-8.
31. Sierra C, López-Soto A, Coca A. Connecting cerebral white matter lesions and hypertensive target organ damage. J Aging Res. 2011;2011:438-978.
32. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit. 2003;8(5):181-5.
33. Salles G, Cardoso C, Nogueira AR, Bloch K, Muxfeldt E. Importance of the eletrocardiographic strain pattern in patients with resistant hypertension. Hypertension. 2006;48(3):437-42.
34. Salles GF, Cardoso CRL, Fiszman R, Muxfeldt ES. Prognostic significance of baseline and serial changes in eletrocardiographic strain pattern in resistant hypertension. J Hypertens. 2010;28(8):1715-23.
35. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framinghan Heart Study. N Engl J Med. 1990;322(22):1561-6.
36. Lonnebaken MT, Rieck AE, Gerdts E. Contrast stress echocardiography in hypertensive heart disease. Cardiovasc Ultrasound. 2011;9:33.
37. Kashgarian M. Hypertensive disease and kidney structure. In: Laragh JH, Brenner BM. (eds). Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press; 1995. p. 433-43.
38. Toto RB. Hypertensive nephrosclerosis in African Americans. Kidney Int. 2003;64(6):2331-41.
39. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al.; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
40. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001,19(11):2063-70.
41. Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic importance of baseline and serial changes in microalbuminuria in patients with resistant hypertension.Atherosclerosis. 2011;216(1):199-204.
42. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50(4):723-8.
43. Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension. Am Heart J. 2010;159(5):833-40.
44. Gonçalves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I, et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest. 2007;132(6):1858-62.
45. Drager LF, Genta PR, Pedrosa RP, Nerbass FB, Gonzaga CC, Krieger EM, et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am J Cardiol. 2010;105(8):1135-9.
46. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-7.
47. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010;52(5):401-9.
48. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150(11):776-83.
49. Drager LF, Queiroz EL, Lopes HF, Genta PR, Krieger EM, Lorenzi-Filho G. Obstructive sleep apnea is highly prevalent and correlates with impaired glycemic control in consecutive patients with the metabolic syndrome. J Cardiometab Syndr. 2009;4(2):89-95.
50. Martins LC, Conceição FL, Muxfeldt ES, Salles GF. Prevalence and associated factors of subclinical hypercortisolism in patients with resistant hypertension. J Hypertens. 2012;30(5):967-73.
51. Boer-Martins L, Figueiredo VN, Demacq C, Martins LC, Consolin-Colombo F, Figueiredo MJ, et al. Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients. Cardiovasc Diabetol. 2011;10:24.
52. Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira Melo S, Coelho OR, et al. Aldosterone excessor escape: treating resistant hypertension. J Clin Hypertens (Greenwich). 2009;11(5):245-52.
53. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-7.
54. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892-6.
55. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000;342(14):1007-14.
56. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92-102.
57. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III--Analysis of data from trials of salt reduction. BMJ. 1991;302(6780):819-24.
58. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA. 1996;275(20):1590-7.
59. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. 2002;16(11):761-70.
60. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65(2 Suppl):643S-651S.
61. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475-81.
62. Wildman RP, Gu D, Muntner P, Huang G, Chen J, Duan X, et al. Alcohol intake and hypertension subtypes in Chinese men. J Hypertens. 2005;23(4):737-43.
63. de Gaudemaris R, Lang T, Chatellier G, Larabi L, Lauwers-Cancès V, Maître A, et al. Socioeconomic inequalities in hypertension prevalence and care: the IHPAF Study. Hypertension. 2002;39(6):1119-25.
64. Aguilera MT, de la Sierra A, Coca A, Estruch R, Fernández-Solá J, Urbano Márquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension. 1999;33(2):653-7.
65. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36(4):594-9.
66. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17(10):904-10.
67. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta analysis of randomized, controlled trials. Hypertension. 2011;58(5):950-8.
68. Bortolotto LA, Malachias MVB, Passarelli Jr O, Póvoa R. Combinações de fármacos anti-hipertensivos na prática clínica. São Paulo: Segmento Farma; 2010. p. 89-100.
69. Mancia G, Laurent S, Rosei-Agabiti E, Ambrosioni E, Burnier M, Caulfield MJ, et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121-58.
70. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, et al.; AngloScandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839-45.
71. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749-57.
72. Hermida RC, Ayala DE, Mojón A, Fernández JR. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am J Hypertens. 2010,23(4):432-9.
73. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens. 2010;23(10):1052-60.
74. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebocontrolled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765-73.
75. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-7.
76. Lozano L, Tovar JL, Sampol G, Romero O, Jurado MJ, Segarra A, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. J Hypertens. 2010;28(10):2161-8.